# Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

> **NCT02693171** · — · TERMINATED · sponsor: **United Therapeutics** · enrollment: 13 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Dinutuximab

## Key facts

- **NCT ID:** NCT02693171
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-15
- **Primary completion:** 2016-12-19
- **Final completion:** 2016-12-19
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2019-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02693171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02693171, "Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02693171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*